The presence of KRAS alterations at the time of resistance to anti-HER2 therapy is consistent with recent data from a clinical trial of trastuzumab and lapatinib in metastatic colorectal cancer (19). This evidence concerns the gene ERBB2 and metastatic colorectal cancer.